Symberix, Inc.

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Symberix is a preclinical-stage company advancing a new class of microbiome-targeting, small-molecule drugs (SYMBIOTIC DRUGS) that work by selectively eliminating harmful microbial activity in the gut without killing beneficial microbes. A spin-out of University of North Carolina at Chapel Hill, Symberix is developing therapeutic adjuncts to mitigate the debilitating lower gastrointestinal (GI) side effects associated with various cancer, pain and immunosuppressive therapies, as well as monotherapies to treat serious lower GI diseases. Symberix’s internal team has a deep understanding of the biology of the microbiome as well as extensive drug discovery, clinical development and commercial biopharma experience. Symberix’s vision is to deliver safe and effective pharmaceutical control of the microbiome.
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
2003
Main Therapeutic Focus:
Lead Product in Development:
SBX-101
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
President and CEO
Symberix, Inc.